Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum YM BioSciences Inc YMI

NYSEAM:YMI - Post Discussion

YM BioSciences Inc > Efficacy
View:
Post by ahnunah on Sep 07, 2009 10:42am

Efficacy

Forgive me if this has been discussed previously on the boards:

On TheStreet.com, Aug. 14 it was said that thus far, the data has shown that Nimotuzumab doesn't have the efficacy of it's competitors.  It doesn't have their side effects as well.

Is this the general understanding of the efficacy of Nimotuzumab?
Comment by DutchGoldMine on Sep 07, 2009 5:31pm
come on DYOR for instance look at the news release of 6/23/2009 and you find this:Results were reported recently at the 2009 ASCO Annual Meeting from arandomized Phase IIb, four-arm, open-label trial of nimotuzumab incombination with radiation therapy (RT) or chemoradiation therapy (CRT)in patients with inoperable, locoregionally advanced Stage III/IVa headand neck cancer conducted in India by ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities